Catalog No.
PMD72101
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse CD314/KLRK1/NKG2D (Phe90-Val232).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
KLRK1, NKG2D, Killer cell lectin-like receptor subfamily K member 1, NKG2-D-activating NK receptor, D12S2489E, NKG2-D type II integral membrane protein, NK cell receptor D, CD314
Purification
Purified by antigen affinity column.
Accession
O54709
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation., PMID:40116579
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214
Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862
Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands., PMID:39582357
MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747
Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity., PMID:39112670
A human autoimmune organoid model reveals IL-7 function in coeliac disease., PMID:39048815
Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer., PMID:39020183
Memory-like differentiation enhances NK cell responses against colorectal cancer., PMID:38737793
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells., PMID:38724464
Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses., PMID:38653235
Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease., PMID:38410511
Natural Killer Cells as a Further Insight into the Course of Chronic Obstructive Pulmonary Disease., PMID:38398020
Evaluation of the TLR3 involvement during Schistosoma japonicum-induced pathology., PMID:38172683
Upregulation of the NKG2D Ligand ULBP2 by JC Polyomavirus Infection Promotes Immune Recognition by Natural Killer Cells., PMID:37774496
Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1., PMID:37773572
Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality., PMID:37753084
IL-17a-producing γδT cells and NKG2D signaling mediate bacterial endotoxin-induced neonatal lung injury: implications for bronchopulmonary dysplasia., PMID:37744375
IL-15 induced bystander activation of CD8+ T cells may mediate endothelium injury through NKG2D in Hantaan virus infection., PMID:36590594
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands., PMID:35970825
CAR-NK Cells: From Natural Basis to Design for Kill., PMID:34970253
Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications., PMID:34486371
Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation., PMID:34294876
Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus., PMID:34012432
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas., PMID:33936075
Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia., PMID:33508619
Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis., PMID:33306195
Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells., PMID:33122138
Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion., PMID:32727790
Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system., PMID:32726145
Human Metapneumovirus Escapes NK Cell Recognition through the Downregulation of Stress-Induced Ligands for NKG2D., PMID:32698530
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting., PMID:32518350
NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells., PMID:32468232
BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma., PMID:32349046
Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases., PMID:32182948
Glycolysis and Oxidative Phosphorylation Play Critical Roles in Natural Killer Cell Receptor-Mediated Natural Killer Cell Functions., PMID:32153568
Enhanced activation of human NK cells by drug-exposed hepatocytes., PMID:32060585
Quantitative analysis of human NK cell reactivity using latex beads coated with defined amounts of antibodies., PMID:32027754
Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells., PMID:31311121
NKG2D-DAP10 signaling recruits EVL to the cytotoxic synapse to generate F-actin and promote NK cell cytotoxicity., PMID:31235500
Cord blood CD4+/CD25+ T cells down-regulates NKG2D on cytokine-induced killer cells., PMID:31136978
Overcoming Target Driven Fratricide for T Cell Therapy., PMID:30619300
A Flow Cytometric NK Cell-Mediated Cytotoxicity Assay to Evaluate Anticancer Immune Responses In Vitro., PMID:30465199
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma., PMID:30455698
Blockade of NKG2D/NKG2D ligand interaction attenuated cardiac remodelling after myocardial infarction., PMID:30307485
For research use only. Not for human or drug use.
